NXC-736 is under clinical development by Nextgen Bioscience and currently in Phase I for Ulcerative Colitis. According to GlobalData, Phase I drugs for Ulcerative Colitis have an 84% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how NXC-736’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
NXC-736 is under development for the treatment of nonalcoholic steatohepatitis, transplant rejection, ulcerative colitis and alopecia areata. It is administered by oral route in the form of tablet. The therapeutic candidate acts by inhibiting NLR family pyrin domain containing 3 (NLRP3), S1PR1 and S1PR2.
For a complete picture of NXC-736’s drug-specific PTSR and LoA scores, buy the report here.